SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is trending as the community discusses its potential and future price targets, with some members expressing strong bullish sentiment and advocating for long-term holding. Recent volatility and a pullback from initial highs have sparked debates about its classification as a potential "scam" versus a promising layer-1 project, while others highlight the importance of considering tokenomics and upcoming unlocks.

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

FLYE is trending due to recent volatile price action and unusually high volume, sparking discussions about a potential short squeeze. The community is weighing the risks of this low-float stock, noting its history of dramatic price swings and reverse splits, while also speculating on possible catalysts for the current movement and comparing it to other similar plays.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

JANX is trending due to a significant after-hours drop following the release of interim data for its JANX007 program, despite some initial interpretations of the results as positive; the community is actively debating whether the data justifies the sharp negative reaction, particularly in comparison to existing treatments like Pluvicto, and focusing on the implications for the company's platform and future data readouts. Discussions also involve speculation about potential buyouts and the company's cash position.

ProShares Trust - ProShares UltraShort Silver -2x Shares

ProShares UltraShort Silver

$ZSL is trending as traders discuss potential short-term pullbacks in silver, looking for opportunities to profit from a reversal. Community members are actively debating entry points, technical indicators, and potential options strategies, with some expressing skepticism towards those heavily promoting silver. Concerns about manipulation and the overall direction of the silver market are also prevalent.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending amid anticipation of HOPE-3 trial data release, with community discussions focused on the potential for positive results and a short squeeze. Concerns about a negative report from Martin Shkreli are countered by optimism surrounding the drug's efficacy and ongoing developments with the StealthX exosome platform. Traders are closely watching for news, potential leaks, and the possibility of a significant price movement.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending following positive analyst coverage and strong performance in the AI infrastructure space, with community members discussing its potential for continued growth and comparing it to competitors. Bullish sentiment is fueled by the company's role in high-speed connectivity solutions for AI data centers, though some caution against its high valuation, as the stock price dipped today.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

MRNA is trending amidst buyout rumors and anticipation surrounding upcoming earnings, as well as an investor day later this month. Community chatter speculates on potential partnerships or a complete acquisition, with some highlighting the company's cash reserves and pipeline value. However, others express concerns about declining revenue, and potential stricter regulatory pathways.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

$MELANIA is seeing active discussion around its performance, with some traders pointing to potential for upside while others remain skeptical, citing past price declines and tokenomics. The coin is also being discussed in the context of other Trump-related assets, with community members debating its overall value and potential as a long-term investment.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending due to a 1-for-10 reverse stock split, leading to discussions about its impact on share value and potential for institutional investment. The community is debating the CEO's motives behind the split and its timing, with some expressing concern about potential dilution and others anticipating a future surge based on cannabis rescheduling news from the Trump administration. Investor sentiment is highly volatile, reflecting uncertainty about the company's direction following the split.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending following news of a collaboration with Bristol Myers Squibb to co-develop a cancer drug, with community members discussing the financial implications of the deal and the potential for future growth in the oncology space.  However, some are wary, pointing to a recent history of insider selling, while others discuss potential links between mRNA vaccines and adverse health outcomes.  Overall sentiment seems mixed with excitement around new developments offset by skepticism related to the company's past.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Hepion Pharmaceuticals Inc. drew heightened attention from retail traders on Monday after the company disclosed that the Nasdaq Hearings Panel had ordered its delisting, citing violations of continued listing requirements.&nbsp;Trading in the company's common stock is set to be suspended at the open on Tuesday, with shares expected to move to the OTC Markets under the same ticker, HEPA.Hepion Pharmaceuticals shares closed down 18.8% at $0.32 on Monday, sliding 45% to $0.17 in after-hours trading.Retail sentiment on Stocktwits turned 'bullish' on Monday amid a 5,100% surge in 24-hour message volume.One user highlighted optimism around Hepion's core asset, Rencofilstat, describing it as a potentially "revolutionary" drug class.&nbsp;Rencofilstat is a cyclophilin inhibitor aimed at treating chronic liver diseases like NASH and hepatocellular carcinoma (HCC).The user suggested that although trial results may not be released soon, the drug could eventually displace existing therapies once they have been fully monetized.&nbsp;They added that the move to OTC "could get interesting."<stembedurl>https://stocktwits.com/BADBOYROY/message/614371348</stembedurl>Another user hoped the stock would be tradable on Robinhood after moving to the OTC market, suggesting the transition could trigger a strong upward move.<stembedurl>https://stocktwits.com/stock_trafficking/message/614386549</stembedurl>The delisting followed Nasdaq's determination that Hepion had failed to maintain the minimum bid price of $1.00 and was in breach of Rule 5101, which allows delisting of companies identified as public shells.Hepion recently entered a license agreement with New Day Diagnostics LLC to distribute tests for celiac disease, respiratory multiplex (COVID-19, Influenza A/B, RSV), H. pylori, and hepatocellular carcinoma (HCC).&nbsp;These tests carry CE marks, making them eligible for sale in Europe.The company had previously paused and then wound down its ASCEND-NASH Phase 2b trial for Rencofilstat, after enrolling 151 patients out of a planned 336.&nbsp;Approximately 80 patients completed a full year of treatment.The stock has declined 98.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Hepion Pharma Stock Draws Bullish Retail Bets Despite Nasdaq Delisting Notice: 'Could Get Interesting'

Despite a sharp decline in stock price, retail traders are optimistic about the company's potential, citing its core asset Rencofilstat and speculating on a rebound following the OTC transition.

Equity

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Hepion Pharmaceuticals announces merger with Pharma Two B Ltd., creating a combined company focused on Parkinson's disease treatment. The merger values Hepion at $58.5 million, and Pharma Two B plans...

Hepion Pharmaceuticals' Strategic Merger and Corporate Restructuring

An update from Hepion Pharmaceuticals (HEPA) is now available. Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. an...

Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?

Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.
read more...

Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...

Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...

Hepion Pharmaceuticals to Present at NASH-TAG 2024

EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic...

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Morristown, NJ.

Hepion Pharmaceuticals Inc

$CRWD

$CRM

$SNOW

$MDB

Which earnings report are you most looking forward to this week? 
 
Drop a comment for others.

Current Price	$0.0745
Prev Close	$0.065
Open	$0.08
Dividend Yield	0.00%
50-Day Moving Average	$0.0688
Beta	1.05
Avg. Volume	24,026.00
PE Ratio	-0.01

52-Week High	$36.73
52-Week Low	$0.033
Market Capitalization	$755,321.00
EPS (Annual)	-$107.35
Price to Book	0.53
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

HEPA
Hepion Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest HEPA News

HEPAHepion Pharmaceuticals Inc